Denatonium Benzoate, the Most Bitter Compound, Reduces Weight by Promoting Adipocyte Browning
Niu Y., Shao J., Teng Y., Zhang C., Xie X., Guo S.
Animal Study, published in Metabolites (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Metabolites (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42042887
- PMCID
- PMC13117511
- DOI
- 10.3390/metabo16040242
Abstract (original English)
Objectives Obesity remains a global health challenge, and promoting white adipose tissue browning has emerged as a promising anti-obesity strategy. This study aimed to investigate the anti-obesity effects of denatonium benzoate (DB) and elucidate its underlying mechanisms. Methods In order to study the anti-obesity effects of DB and its mechanisms, we used in vivo and in vitro obesity models to study whether DB has anti-obesity effects by participating in fat browning. We investigated the role of DB in high-fat diet (HFD)-induced obese C57BL/6J mice using 36 male animals (8 weeks old, 25 ± 2 g), and evaluated the expression of the adipogenic marker genes Fatty acid-binding protein 4 ( Fabp4 ) and Peroxisome Proliferator-Activated Receptor gamma ( PPAR-γ ); the thermogenic genes uncoupling protein 1 ( Ucp1 ), Transcription Factor A, Mitochondrial ( TFAM ), Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha ( Pgc1α ), and Adrenergic receptor beta 3 ( Adrb3 ); as well as the adipose browning marker genes Deiodinase, Iodothyronine, Type II ( Dio2 ), PR domain containing 16 ( PRDM16 ), and Peroxisome Proliferator-Activated Receptor alpha ( PPAR-α ) in 3T3-L1 cells and primary adipocytes with DB treatment. Conclusions These results indicate that the anti-obesity effects of DB may be related to the browning of white fat, providing a novel potential candidate for anti
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.